Glaucoma is the leading cause of irreversible blindness, and its treatment is attracting widespread attention. Drug-loaded lacrimal suppositories can effectively treat xerophthalmia, but there is little research on the treatment of glaucoma with drug-loaded lacrimal suppositories. This article explored and expanded the non-pharmacological model of lacrimal suppository therapy for glaucoma by using a combination of lacrimal suppository and medication. The drug-loaded lacrimal suppository was rationally designed through the conjugation of gelatin with polyamide (PAM) via the formation of amide linkages, followed by Schiff base reaction grafting with latanoprost. In vitro drug release studies showed that latanoprost released from drug-loaded lacrimal embolus had sustained-release properties with a release time of 33 days and a drug release volume of 82.6%. The biological evaluation of drug-loaded lacrimal thrombus was carried out by IOP test, retinal potential test, and retinal H&E staining. The results showed that the IOP decreased to 27.125 ± 1.1254 mmHg, and the a and b waves of retinal potential increased to 4.39 ± 0.16 μV and 67.9 ± 2.17 μV, respectively. It indicated that latanoprost lacrimal suppository has a good therapeutic effect on glaucoma.
ElGoharyAAElshazlyLHM. Photopic negative response in diagnosis of glaucoma:an experimental study in glaucomatous rabbit model. Int J Ophthalmol2015; 3: 459–464.
2.
ShahiwalaA. Hydrogel based formulations in treatment of glaucoma. Novel Approaches Drug Des Dev2020; 5(3): 39–41.
3.
YousefPMarziyehFYadollahO, et al.Synthesis and characterization of timolol maleate-loaded quaternized chitosan-based thermosensitive hydrogel: A transparent topical ocular delivery system for the treatment of glaucoma. Int J Biol Macromol2020; 159: 117–128.
4.
AmoEUrttiA. Current and future ophthalmic drug delivery systems. A shift to the gposterior segment. Drug Discov Today2008; 13(3–4): 135–143.
5.
DingSL. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today1998; 36(8): 328–335.
6.
LaiJYLuoLJNguyenDD. Multifunctional glutathione-dependent hydrogel eye drops with enhanced drug bioavailability for glaucoma therapy. Chem Eng J2020: 126190.
7.
AriturkNOgeIErkanD, et al.The effects of nasolacrimal canal blockage on topical medications for glaucoma. Acta Ophthalmol Scan2010; 74(4): 411–413.
8.
FedorchakMVConnerIPSchumanJS, et al.Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci Rep2017; 7(1): 8639.
9.
MaWDXuHWangC, et al.Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Ophthalmol2008; 350(1–2): 247–256.
10.
NovackGD. Ophthalmic drug delivery: development and regulatory considerations. Clin Pharmacol Ther2009; 85(5): 539–543.
11.
RathoreKSNemaRK. Review on ocular inserts. Int J Pharmtech Res2009; 1(2): 164–169.
12.
HorneRRJuddKEPittWG. Rapid loading and prolonged release of latanoprost from a silicone hydrogel contact lens. J Drug Deliv Sci Tec2017; 41: 410–418.
13.
JungHJAbou-JaoudeMCarbiaBE, et al.Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release2013; 165(1): 82–89.
14.
MaulviFALakdawalaDHShaikhAA, et al.In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. J Control Release2016; 226: 47–56.
15.
LeeDChoSParkHS, et al.Ocular drug delivery through pHEMA-hydrogel contact lenses co-loaded with lipophilic vitamins. Sci Rep2016; 6: 34194.
16.
Ortiz-BassoTGalmariniAVigoRL, et al.The relationship between topical anti-glaucoma medications and the development of lacrimal drainage system obstruction. Arq Bras Oftalmol2018; 81(6): 490–493.
17.
KompellaUBKadamRSLeeVH. Recent advances in ophthalmic drug delivery. Ther Deliv2010; 1(3): 435–456.
18.
CHEES. Moxifloxacin punctum plug for sustained drug delivery. J Ocul Pharmacol Th2012; 28(4): 340–349.
19.
YellepeddiVKSheshalaRMcMillanH, et al.Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discov Today2015; 20(7): 884–889.
20.
BaxterSALaibsonPR. Punctal plugs in the management of dry eyes. Ocul Surf2004; 2(4): 255–265.
21.
ChengYHTsaiTHJhanYY, et al.Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohyd Polym2016; 144: 390–399.
22.
SawhneyASJarrettPBassettM, et al.Drug Delivery through Hydrogel Plugs. CA, CA2750242 A12010.
KulkarniGTSethiNAwasthiR, et al.Development of ocular delivery system for glaucoma therapy using natural hydrogel as film forming agent and release modifier. Polim Med2016; 46(1): 25–33.
25.
WangJLiBHuangD, et al.Nano-in-nano dendrimer gel particles for efficient topical delivery of antiglaucoma drugs into the eye. Chem Eng J2021; 425: 130498.
26.
WaduthanthriKDHeYMontemagnoC, et al.An injectable peptide hydrogel for reconstruction of the human trabecular meshwork. Acta Biomater2019; 15: 137–143.
27.
CasolaroMCasolaroI. Controlled release of antidepressant drugs by multiple stimuli-sensitive hydrogels based on α-aminoacid residues. J Drug Deliv Sci Tech2015; 30: 82–89.
28.
GuptaDTatorCHShoichetMS. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. Biomater2006; 27(11): 2370–2379.
29.
SlaughterBVKhurshidSSFisherOZ, et al.Hydrogels in regenerative medicine. Adv Mater2010; 21(32–33): 3307–3329.
30.
MullarneyMPSeeryTWeissRA. Drug diffusion in hydrophobically modified N,N-dimethylacrylamide hydrogels. Polym2006; 47(11): 3845–3855.
31.
WuHLiuSXiaoL, et al.Injectable and pH-responsive silk nanofiber hydrogels for sustained anticancer drug delivery. Acs Appl Mater Inter2016; 8: 17118–17126.
32.
ZhangYChenYShenX, et al.Reduction- and pH-sensitive lipoic acid-modified poly (L-lysine) and polypeptide/silica hybrid hydrogels/nanogels. Polym2016; 86: 32–41.
33.
BrombergLERonES. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv Drug Deliver Rev1998; 31(3): 197–221.
34.
TanHRamirezCMMiljkovicN, et al.Thermosensitive injectable hyaluronic acid hydrogel for adipose tissue engineering. Biomater2009; 30(36): 6844–6853.
35.
TamesueSTakashimaYYamaguchiH, et al.Photoswitchable supramolecular hydrogels formed by cyclodextrins and azobenzene polymers. Angew Chem Int Edi2010; 49(41): 7461–7464.
36.
LimHLChuangJCTranT, et al.Dynamic electromechanical hydrogel matrices for stem cell culture. Adv Funct Mater2011; 21(1): 55–63.
37.
FuXHosta-RigauLChandrawatiR, et al.Multi-stimuli-responsive polymer particles, films, and hydrogels for drug delivery. Chem2018; 4(9): 2084–2107.
38.
SinghVBushettiSAppalaR, et al.Stimuli-sensitive hydrogels: a novel ophthalmic drug delivery system. Indian J Ophthalmol2010; 58(6): 477–481.
39.
YunJZ. Effects of endoscopic cyclophotocoagulation combined with phacoemulsification and IOL implantation on intraocular pressure in rabbit glaucoma models. Chin J Exp Ophthalmol2015; 3: 232–236.
40.
ChenKYuYNgSH, et al.Intracameral injection of a chemically cross-linked hydrogel to study chronic neurodegeneration in glaucoma. Acta Biomater2019; 94: 219–231.
41.
BigiACojazziGPanzavoltaS, et al.Mechanical and thermal properties of gelatin films at different degrees of glutaraldehyde crosslinking. Biomater2001; 22(8): 763–768.
42.
MarioCBarbaraDBEmiliaM. Hydrogel containing L-valine residues as a platform for cisplatin chemotherapy. Colloid Surf B2011; 88(1): 389–395.
43.
HanQWangYLiX, et al.Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery. J Mater Sci Mater Med2015; 26(8): 1–9.
44.
RkasMX. Glaucoma implant for the management of glaucoma in nave patients versus patients with previous glaucoma surgery. J Clin Med2021; 10(19): 4417.
45.
BouhenniRADunmireJSewellA, et al.Animal models of glaucoma. Biomed Res Int2012; 2012(3): 692609.
